Accendra Health, Inc. (ACH)
| Market Cap | 184.98M |
| Revenue (ttm) | 2.76B |
| Net Income (ttm) | -1.10B |
| Shares Out | 76.44M |
| EPS (ttm) | -14.32 |
| PE Ratio | n/a |
| Forward PE | 4.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 924,029 |
| Open | 2.400 |
| Previous Close | 2.420 |
| Day's Range | 2.310 - 2.435 |
| 52-Week Range | 1.840 - 10.430 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | 3.38 (+39.67%) |
| Earnings Date | Feb 19, 2026 |
About ACH
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines includi... [Read more]
Financial Performance
In 2025, Accendra Health's revenue was $2.76 billion, an increase of 3.06% compared to the previous year's $2.68 billion. Losses were -$1.10 billion, 203.5% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ACH stock is "Buy." The 12-month stock price target is $3.38, which is an increase of 39.67% from the latest price.
News
Accendra Health: Debt Reduction Creates Long-Term Opportunity (Upgrade)
Accendra Health is upgraded to "Buy" after severe underperformance, trading at just 2x 2027 free cash flow. ACH faces significant margin pressure and a challenging balance sheet, with net leverage exp...
Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript
Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript
Accendra Health Reports Fourth Quarter 2025 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect th...
Accendra Health Announces Fourth Quarter 2025 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends o...
Accendra Health, Inc. to Begin Trading on NYSE under New Ticker “ACH”
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) announced that the Company's common stock will begin trading on the New York Stock Exchange under its new ticker symbo...
Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) (the “Company”) announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to...
Owens & Minor Announces Corporate Name Change to Accendra Health, Inc.
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) (“the Company”) today announced that it will change its name to Accendra Health, Inc. with an anticipated effective date of December 31,...
Owens & Minor, Inc. (OMI) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Owens & Minor, Inc. (OMI) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global ...
Owens & Minor, Inc. (OMI) Q3 2025 Earnings Call Transcript
Owens & Minor, Inc. ( OMI) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Will Parrish Edward Pesicka - President, CEO & Director Jonathan Leon - Executive VP, CFO & Corporat...
Owens & Minor Reports Third Quarter 2025 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the third quarter ended September 30, 2025. Unless otherwise noted, the results herein reflect the ...
Owens & Minor Announces Date and Time Change of Third Quarter 2025 Financial Results and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the third quarter of 2025 on Thursday, October 30, 2025, after trading ends on the New York Stock...
PLATINUM EQUITY TO ACQUIRE PRODUCTS & HEALTHCARE SERVICES BUSINESS FROM OWENS & MINOR
Standalone P&HS anticipated to benefit from Platinum's carve-out experience, sector expertise and commitment to growth Owens & Minor to retain a 5% equity stake in the business LOS ANGELES , Oct. 7, 2...
Owens & Minor Announces Definitive Agreement to Divest Products & Healthcare Services Segment to Platinum Equity for $375mm in Cash and a Retained Equity Stake
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today announced that it has entered into a definitive agreement for the sale of the Company's Products & Healthcare Services (P&HS) segm...
Apria and Byram Join New Optum Preferred DME Network
RICHMOND, Va.--(BUSINESS WIRE)--Effective September 1, 2025, Apria and Byram, part of the Owens & Minor family, entered a new national provider agreement with Optum Health.
AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
NEW YORK , Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the ...
Owens & Minor Analysts Boost Their Forecasts After Q2 Results
Owens & Minor, Inc. OMI reported worse-than-expected second-quarter earnings on Monday.
Owens & Minor: An Extreme Reached Amid Disastrous Results (Rating Upgrade)
Owens & Minor, Inc.'s disastrous performance, weak margins, and strategic missteps have eroded investor confidence and driven OMI stock down 70% in a year. The planned sale of its core Products & Heal...
Owens & Minor, Inc. (OMI) Q2 2025 Earnings Call Transcript
Owens & Minor, Inc. (NYSE:OMI) Q2 2025 Earnings Conference Call August 11, 2025 8:30 AM ET Company Participants Jacqueline Marcus - IR, Alpha IR Group LLC Edward A. Pesicka - President, CEO & Directo...
US Stocks Mixed; Owens & Minor Posts Downbeat Earnings
U.S. stocks traded mixed this morning, with the Nasdaq Composite declining around 0.2% on Monday.
Owens & Minor Reports Second Quarter 2025 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the second quarter ended June 30, 2025. In connection with a likely sale of the Company's Products ...
Top Wall Street Forecasters Revamp Owens & Minor Expectations Ahead Of Q2 Earnings
Owens & Minor, Inc. OMI will release earnings results for the second quarter before the opening bell on Monday, Aug. 11.
Owens & Minor Announces Second Quarter 2025 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the second quarter of 2025 on Monday, August 11, 2025, before trading begins on the New York Stoc...
Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Previously Announced Acquisition
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the...
Owens & Minor: FTC Approval And Stock Repurchases Could Trigger The Stock Price
OMI is undervalued, with catalysts including FTC approval for the Rotech acquisition and a potential segment sale that could boost cash and reduce net debt. The company's share buybacks at $8.66 and r...